Similar articles

• Use of intravenous pH 4.0 treated gamma globulin in humoral immunodeficiency disease.

  Cunningham-Rundles C, Smithwick EM, Siegal FP, Day NK, Lion A, O'Malley J, Barandun S, Good RA. Cunningham-Rundles C, et al. Birth Defects Orig Artic Ser. 1983;19(3):201-3. Birth Defects Orig Artic Ser. 1983. PMID: 6197105 Clinical Trial. No abstract available.
• Intravenous gamma-globulin: clinical applications in pediatric care.

  Ott MJ, Senner A, Esker S, Knapp R, Bolinger AM. Ott MJ, et al. J Pediatr Nurs. 1990 Oct;5(5):307-15. J Pediatr Nurs. 1990. PMID: 1698963 Review.
• Intravenous immune globulin and the compromised host. Proceedings of a symposium, September 2l to 23, 1983, Dallas.

  [No authors listed] [No authors listed] Am J Med. 1984 Mar 30;76(3A):1-231. Am J Med. 1984. PMID: 6201066 No abstract available.
• [Treatment of primary immunodeficiencies with intravenous gamma globulin].

  García Rodríguez C, López Trascasa M, Ferreira Cerdán A, Fontán Casariego G. García Rodríguez C, et al. An Esp Pediatr. 1987 Dec;27(6):411-5. An Esp Pediatr. 1987. PMID: 2451892 Spanish.
• The role of anti-IgA antibodies in causing adverse reactions to gamma globulin infusion in immunodeficient patients: a comprehensive review of the literature.

  Rachid R, Bonilla FA. Rachid R, et al. J Allergy Clin Immunol. 2012 Mar;129(3):628-34. doi: 10.1016/j.jaci.2011.06.047. Epub 2011 Aug 11. J Allergy Clin Immunol. 2012. PMID: 21835445 Review.